Nadia Waheed, M.D., Chief Medical Officer
London, UK
Our ultimate goal is to slow, or possibly stop, the progression of dry-AMD. Patients in our Phase I/II clinical trial, known as the FOCUS study, receive a single dose of GT005 through an injection below their retina. Syncona, our lead investor, helped us create the only retinal gene therapy company to combine discovery research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London, UK, with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness.

By using this website you agree to accept our Privacy Policy and Terms & Conditions